Pharmaceutical

Travere signs $120m licensing deal with Renalys for sparsentan in Asia

Renalys plans to start a registrational trial for sparsentan as a treatment for IgA nephropathy in Japan in Q2 2024.

Jan 27, 2024 - 18:00
Travere signs $120m licensing deal with Renalys for sparsentan in Asia
Renalys plans to start a registrational trial for sparsentan as a treatment for IgA nephropathy in Japan in Q2 2024.
Read the original article

Tags:

Previous Article

FDA expands approval of Dupixent for eosinophilic esophagitis in children

Next Article

STAT+: From a small town in Wales, a scientific sleuth has shaken Dana-Farber — ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Touchlight joins forces with University of Liverpool for NSCLC vaccine

Touchlight joins forces with University of Liverpool fo...

Apr 5, 2024

Boehringer and CBmed partner to develop cancer therapies

Boehringer and CBmed partner to develop cancer therapies

Feb 10, 2024

STAT+: FTC move to block the Amgen-Horizon deal highlights concerns over negotiations with insurers

STAT+: FTC move to block the Amgen-Horizon deal highlig...

May 17, 2023